10
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Inmunogenicidad de la vacuna Heberbiovac-HB en ancianos

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Se le aplicó la vacuna recombinante cubana contra el virus de la hepatitis B Herberbiovac HB a un grupo de individuos mayores de 65 a pertenecientes a un hogar de ancianos de Ciudad de La Habana, a la dosis de 20 myg, con el esquema 0, 1 y 6 meses, para estudiar su inmunogenicidad, la cual fue evaluada a los 2, 7 y 12 meses después de aplicada la primera dosis,. A los 60 d se obtuvo 47,1 % de títulos protectores y media geométrica de 6,04 UI/L. Cuando se evaluó la respuesta inmune a los 7 meses se logró 100,0 % de seroconversión (1 UI/L) y seroprotección ( 10 UI/L) y media geométrica de 136,93 UI/L. Finalmente, al año, la seroconversión y la seroprotección también fueron del 100 %, y la media geomètrica de 204,61 UI/L. Se demostrò el alto poder inmunogénico de esta vacuna, lo que la hace recomendable para su uso en la protección contra el virus de la hepatitis B, en este grupo de edad.

          Translated abstract

          The Cuban recombinant vaccine against the hepatitis B virus was applied to a group of individuals over 65 from a geriatric home in Havana City. Dose of 20 ìg were administered within a scheme from 0.1 to 6 months in order to study its immunogenecity, which was evaluated at 2,7, and 12 months after the first dose. 47.1 % of protective titres and geometrical mean of 6.04 UI/L were obtained after 60 days. 100 % of seroconversion ( UI/L) and seroprotection (10 UI/L) and geometric mean of 136.93 UI/L were obtained when the immune response was evaluated on the 7th month. Finally, after a year, seroconversion and seroprotection were also of 100 %, and the geometric mean was of 204.61 UI/L. It was proved the high immunogenic power of this vaccine, which makes it recommendable to protect this age group from the hepatitis B virus.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP).

          (1991)
          The following statement updates all previous recommendations on protection against hepatitis B virus infection, including use of hepatitis B vaccine and hepatitis B immune globulin for prophylaxis against hepatitis B virus infection (MMWR 1985;34:313-24,329-35, MMWR 1987;36:353-66, and MMWR 1990:39 [No.RR-2]:8-19) and universal screening of pregnant women to prevent perinatal hepatitis B virus transmission (MMWR 1988;37:341-46,51, and MMWR 1990;39[No.RR-2]:8-19). Recommendations concerning the prevention of other types of viral hepatitis are found in MMWR 1990;39(No.RR-2):1-8, 22-26. This document provides the rationale for a comprehensive strategy to eliminate transmission of hepatitis B virus in the United States. This prevention strategy includes making hepatitis B vaccine a part of routine vaccination schedules for all infants.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine.

            Recombinant deoxyribonucleic acid technology has permitted the development of a vaccine from the hepatitis B surface antigen expressed in genetically manipulated yeast cells. Clinical trials with the vaccine were started in February 1984 and, to date, have involved more than 12,500 persons. The vaccine has been shown to be safe, well tolerated, and immunogenic in healthy persons of all ages and in special target groups likely to require vaccination. The vaccine's protective efficacy has been established in three groups at high risk for hepatitis B infection--homosexual men, institutionalized mentally handicapped patients, and neonates of mothers who are chronic carriers. Production of this vaccine on a large scale should make it less expensive than plasma-derived vaccines and thus broaden the indications for vaccination.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Control de la hepatitis viral

              (1987)
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                mtr
                Revista Cubana de Medicina Tropical
                Rev Cubana Med Trop
                Centro Nacional de Información de Ciencias Médicas (Ciudad de la Habana )
                1561-3054
                December 1996
                : 48
                : 3
                : 200-203
                Affiliations
                [1 ] Universidade Estadual de Maringá Brazil
                Article
                S0375-07601996000300015
                cacd338c-3724-4b87-9d52-2b3781e90025

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Cuba

                Self URI (journal page): http://scielo.sld.cu/scielo.php?script=sci_serial&pid=0375-0760&lng=en
                Categories
                TROPICAL MEDICINE

                Infectious disease & Microbiology
                HEPATITIS B VACCINES,VACCINES, SYNTHETIC,HEPATITIS B ANTIBODIES,AGED,VACUNAS CONTRA HEPATITIS B,VACUNAS SINTÉTICAS,ANTICUERPOS DE LA HEPATITIS B,ANCIANOS

                Comments

                Comment on this article